Vertex Pharmaceuticals (NASDAQ:VRTX) beat Q1 2026 profit estimates as ALYFTREK sales surged 687% year-over-year. Revenue missed forecasts at USD 2.99 billion, but EPS of USD 4.47 topped consensus. Full-year guidance reiterated at USD 12.95–USD 13.1 billion.

Key Highlights:

  • Q1 2026 EPS of USD 4.47 beat analyst consensus of USD 4.31 by 3.7%
  • ALYFTREK sales surged 687% year-over-year to USD 424.4 million
  • Total revenue of USD 2.99 billion missed forecasts by roughly 1%
  • JOURNAVX surpassed 1 million cumulative prescriptions since launch
  • Full-year revenue guidance reaffirmed at USD 12.95–USD 13.1 billion

A Profitable Quarter With a Revenue Asterisk

Vertex Pharmaceuticals (NASDAQ:VRTX) reported first-quarter 2026 results that offered a structurally important signal: its revenue mix is shifting faster than Wall Street had modelled, and the transition is not yet complete.

Adjusted earnings per share of USD 4.47 cleared the consensus estimate of USD 4.31. Total product revenue reached USD 2.99 billion, up 8% year-over-year, but fell roughly 1% short of the USD 3.02–USD 3.03 billion analysts had anticipated. The gap reflects a transitional dynamic within the cystic fibrosis franchise, where the new once-daily therapy ALYFTREK is displacing TRIKAFTA faster than implied revenue estimates had assumed.

Vertex has dominated treatment of cystic fibrosis (CF), a hereditary disease where defective cell membrane function progressively damages the lungs and digestive system, for over a decade, and the commercial transition now underway within its CF portfolio reflects both the depth of that dominance and the pace of clinical advancement within it.

ALYFTREK, approved in the United States in December 2024, recorded USD 424.4 million in first-quarter sales, a near eightfold increase from USD 53.9 million in the same period a year earlier. The older TRIKAFTA, meanwhile, generated USD 2.35 billion, falling short of analyst expectations of USD 2.64 billion. The aggregate CF revenue outcome was softer than forecast, but the composition matters strategically: ALYFTREK carries a differentiated clinical profile, including improved sweat chloride outcomes and once-daily dosing, which underpins long-term patient retention and pricing durability.

Operating income on a non-GAAP basis reached USD 1.31 billion, an 11% improvement year-over-year, demonstrating continued cost discipline against a 5% rise in combined operating expenses to USD 1.29 billion. The company ended the quarter with USD 13 billion in cash and investments, having deployed USD 344 million to repurchase over 741,000 shares.

Diversification Gaining Commercial Traction

Beyond cystic fibrosis, two newer assets contributed approximately 25% of total year-over-year revenue growth in the quarter, a proportion that management expects to expand through 2026.

CASGEVY, the gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia developed jointly with CRISPR Therapeutics, generated USD 43 million in first-quarter revenue. More than 500 patients have initiated the treatment journey since launch, with hundreds completing cell collection and infusions underway. A pricing agreement secured in Germany broadens reimbursement access in a major European market. Management maintains a full-year target of USD 500 million or more from non-CF products, with CASGEVY contributing meaningfully to that figure.

JOURNAVX, the non-opioid acute pain treatment launched in March 2025, recorded USD 29 million in revenue on more than 350,000 filled prescriptions in the quarter, compared with roughly 550,000 for the entirety of 2025. The company has now secured coverage for 240 million lives across commercial PBMs, with two of four major Medicare Part D plans confirming coverage effective May 1. Management expects gross-to-net to normalize through the second half of 2026 as patient support programs taper, with revenue growth expected to outpace prescription growth in that period.

Pipeline Progress and One Notable Discontinuation

On the research front, Vertex disclosed the discontinuation of VX-522, its mRNA-based therapy targeting CF patients who produce no CFTR protein, a group of approximately 5,000 individuals ineligible for modulator therapy. The program encountered persistent lung inflammation likely associated with the lipid nanoparticle delivery mechanism. Management acknowledged the setback but reiterated commitment to finding alternative delivery modalities for this patient subset.

Offsetting this, the renal pipeline delivered material clinical progress. Povotacicept, a dual BAFF/APRIL inhibitor, achieved statistically significant results across all primary and secondary endpoints in the Phase III RAINIER interim analysis for IgA nephropathy, including a 52% reduction in proteinuria versus baseline. A BLA filing followed within 27 days of database lock, the fastest regulatory submission in company history. Management is positioning povotacicept as a potential fourth commercial franchise alongside CF, hematology, and pain.

Guidance Reaffirmed; Execution Risk Acknowledged

Vertex reiterated its 2026 revenue guidance of USD 12.95–USD 13.1 billion, implying 8–9% growth, alongside non-GAAP operating expense guidance of USD 5.65–USD 5.75 billion. The company expressed no material tariff exposure for the current fiscal year. Forward EPS projections point to USD 4.75 for Q2 2026 and USD 5.14 for Q1 2027, though it is worth noting that a number of analysts have revised near-term earnings estimates downward ahead of the next reporting period.

For investors, the quarter's core message is one of controlled transition rather than structural weakness. The erosion in TRIKAFTA revenue is deliberate, driven by a clinically superior successor already gaining momentum. With a renal franchise approaching its first regulatory milestone, non-opioid pain coverage expanding, and $13 billion in cash providing strategic flexibility, Vertex enters the remainder of 2026 with its franchise architecture broadening in both disease area and geographic reach. The revenue miss this quarter is a footnote; the construction underway is the headline.